{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-007832","form_type":"8-K","ticker":"GKOS","cik":"0001192448","company_name":"GLAUKOS Corp","filed_at":"2023-05-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.166211+00:00","generated_at":"2026-06-16T00:21:09.901262+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Glaukos Q1 net sales rise 9% to $73.9M; guides 2023 sales up; GAAP net loss widens to $34.6M","bullets":["Q1 2023 net sales $73.9M (+9% YoY); glaucoma $56.2M (+9%), corneal health $17.7M (+10%).","GAAP net loss $34.6M ($0.72 loss per share) vs net income $5.4M ($0.11) in Q1 2022.","Non-GAAP net loss $28.4M ($0.59) vs prior-year non-GAAP net loss $18.1M ($0.38).","Raised 2023 net sales guidance to $295-300M from $290-295M.","Operating expenses increased sharply: SG&A +22%, R&D +31%; ended Q1 with $325M cash."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-007832","json":"https://secwatch.observer/filing/0001558370-23-007832.json","markdown":"https://secwatch.observer/filing/0001558370-23-007832.md","text":"https://secwatch.observer/filing/0001558370-23-007832.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1192448/000155837023007832/0001558370-23-007832-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1192448/000155837023007832/gkos-20230503x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-16T00:21:09.901262+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e861751ae20a66e4616be3b950940c2526c14e15","claim":"GLAUKOS Corp reported the first quarter ended March 31, 2023 results: revenue $73.9 million, net income $34.6 million, EPS ($0.72) per diluted share. Guidance raised.","evidence_excerpt":"of glaucoma, corneal disorders and retinal diseases, today announced financial results for the first quarter ended March 31, 2023. Key highlights include: ● Net sales of $73.9 million in Q1 2023 increased 9% year-over-year on a reported basis and 11% year-over-year on a constant currency basis. ● Glaucoma net sales of $56.2 million in Q1 2023 increased 9%","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1192448/000155837023007832/0001558370-23-007832-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2023"},{"label":"Revenue","value":"$73.9 million"},{"label":"Net income","value":"$34.6 million"},{"label":"EPS","value":"($0.72) per diluted share"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}